Significance of TP53 mutations as predictive markers of adjuvant cisplatin‐based chemotherapy in completely resected non‐small‐cell lung cancer

Adjuvant cisplatin‐based chemotherapy only marginally improves survival in patients with completely resected non‐small‐cell lung cancer (NSCLC). We have evaluated the predictive value of mutations in TP53, encoding the tumour suppressor p53, in the International Adjuvant Lung Cancer Trial (IALT), a...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Mol Oncol
Asıl Yazarlar: Ma, Xiaoli, Rousseau, Vanessa, Sun, Haiji, Lantuejoul, Sylvie, Filipits, Martin, Pirker, Robert, Popper, Helmut, Mendiboure, Jean, Vataire, Anne-Lise, Le Chevalier, Thierry, Soria, Jean Charles, Brambilla, Elisabeth, Dunant, Ariane, Hainaut, Pierre
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2014
Konular:
Research Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528648/
https://ncbi.nlm.nih.gov/pubmed/24495481
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2013.12.015
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller